Inhibition of tau-mediated early synaptic dysfunction KU Leuven
The present invention relates to the field of neurodegenerative diseases, including Tauopathies, and the prevention and/or treatment of the early synaptic dysfunction arising in patients thereof. In particular, the present invention relates to screening methods for producing compounds which can prevent the early synaptic dysfunction by inhibiting the reduction of synaptic vesicle mobilization and neurotransmitter release and which can prevent early pathology in varies Tauopathies.